Nab-paclitaxel + Carboplatin

DRUG4 trials

Sponsors

Hebei Medical University Fourth Hospital, Eikon Therapeutics, Haisco Pharmaceutical Group Co., Ltd.

Conditions

Advanced Solid TumorsBreast CancerNab-paclitaxelNon Small Cell Lung Cancer (Squamous or Non Squamous)Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma (mPDAC)Stage 4 NSCLCTriple Negative Breast Cancer

Phase 1

HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

Not yet recruitingNCT07699757

Haisco Pharmaceutical Group Co., Ltd.Advanced Solid Tumors, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)

Start: 2026-07-01End: 2029-11-01Target: 258Updated: 2026-07-14

Phase 2

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

RecruitingNCT04138719

Hebei Medical University Fourth HospitalBreast Cancer, Nab-paclitaxel, Triple-negative Breast Cancer

Start: 2019-11-20End: 2028-06-20Target: 520Updated: 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

RecruitingNCT04159142

Hebei Medical University Fourth HospitalNab-paclitaxel, Triple Negative Breast Cancer

Start: 2019-11-20End: 2028-09-20Target: 414Updated: 2025-09-11

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

RecruitingNCT07365319

Eikon TherapeuticsNon Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

Start: 2026-06-15End: 2040-12-31Target: 750Updated: 2026-07-15